Eli Lilly and Company. (Active Pharmaceutical Ingredient Watch).(receives letter of approval to market Cymbalta)(Brief Article)

Chemical Market Reporter, September, 2002

ELI LILLY and Company received an approvable letter from the Food and Drug Administration fur Cymbalta (duloxetine), a dual reuptake inhibitor that works through two key neurotransmitters involved in depression--serotonin and norepinephrine.

Premium Content Partnership | HighBeam Research provides an in-depth online archive library of reference works. HighBeam Research

 

BNET TalkbackShare your ideas and expertise on this topic

Please add your comment:

  1. You are currently: a Guest |
  2.  

Basic HTML tags that work in comments are: bold (<b></b>), italic (<i></i>), underline (<u></u>), and hyperlink (<a href></a)

advertisement
Click Here
advertisement
  • Click Here
  • Click Here
  • Click Here
advertisement
Click Here